Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 2019, 6315936
eCollection

HER2, NF- κ B, and SATB1 Expression Patterns in Gastric Cancer and Their Correlation With Clinical and Pathological Parameters

Affiliations

HER2, NF- κ B, and SATB1 Expression Patterns in Gastric Cancer and Their Correlation With Clinical and Pathological Parameters

Marta Smolińska et al. Dis Markers.

Abstract

Gastric cancer (GC) is currently recognized as one of the most common and fatal tumor worldwide. The identification of novel biomarkers in relation to clinical information as well as extending the knowledge on a multiple crosstalk between various oncogenic pathways implicated in GC carcinogenesis seems pivotal to limit the disease-associated mortality. Therefore, we assessed the expression of HER2, NF-κB, and SATB1 in a total of 104 gastric adenocarcinomas and 30 normal gastric samples and correlated the expression patterns with each other and with some clinicopathological variables. Protein expression was examined by immunohistochemistry (IHC) on tissue microarrays (TMAs), and fluorescence in situ hybridization (FISH) was employed to detect HER2 amplification. In the studied group, HER2 and SATB1 were found to be overexpressed in gastric cancer tissue in comparison to normal gastric mucosa. The expression status of the former protein was seen to differ according to some clinicopathological features, but without statistical significance, whereas the expression of the latter was not importantly associated with any of them. In turn, the NF-κB protein level was significantly related to the presence of lymph node metastasis. HER2 expression was not significantly correlated with that of other proteins, but a positive correlation was found between the expression of SATB1 and NF-κB. Further studies with a larger group of patients combined with in vitro mechanistic experiments are required to fully elucidate the role and relationship of HER2, NF-κB, and SATB1 expression in gastric cancer progression. However, to the best of our knowledge, this study is the first look at a simultaneous evaluation of these three markers in the samples of gastric cancer patients.

Conflict of interest statement

The authors declare that there is no conflict of interest regarding the publication of this article.

Figures

Figure 1
Figure 1
Immunohistochemical analysis of HER2 expression in gastric adenocarcinoma (primary magnification ×10). (a) Negative expression of HER2. (b) Score 2+ basolateral membrane staining for HER2. (c) Positive strong reaction (3+) basolateral membrane staining for HER2. (d) Control tissue of normal gastric mucosa.
Figure 2
Figure 2
Representative cases of FISH analysis in gastric cancer (a, b). Case with HER2 amplification using FISH analysis. Green signals refer to the probe of Chr. 17 centromere, while red signals are the target probe for HER2 (primary magnification, ×100).
Figure 3
Figure 3
Immunohistochemical analysis of NF-κB and SATB1 expression in gastric cancer tissues (primary magnification ×10). (a) Negative expression of NF-κB. (b) Strong positive (3+) nuclear and cytoplasmic staining for NF-κB. (c) NF-κB control tissue of normal gastric mucosa. (d) Negative expression of SATB1. (e) Strong positive (3+) nuclear staining for SATB1. (f) SATB1 control tissue of normal gastric mucosa.
Figure 4
Figure 4
Correlation between HER2, NF-κB, and SATB1 expression in gastric cancer tissues. Correlation values are presented in a heat map (Spearman correlation test).

Similar articles

See all similar articles

References

    1. Ferlay J., Soerjomataram I., Dikshit R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015;136(5):E359–E386. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. Lin X., Zhao Y., Song W.-M., Zhang B. Molecular classification and prediction in gastric cancer. Computational and Structural Biotechnology Journal. 2015;13:448–458. doi: 10.1016/j.csbj.2015.08.001. - DOI - PMC - PubMed
    1. Takahashi N., Yamada Y., Taniguchi H., et al. Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer. BMC Research Notes. 2014;7(1):p. 271. doi: 10.1186/1756-0500-7-271. - DOI - PMC - PubMed
    1. Karimi P., Islami F., Anandasabapathy S., Freedman N. D., Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiology, Biomarkers & Prevention. 2014;23(5):700–713. doi: 10.1158/1055-9965.EPI-13-1057. - DOI - PMC - PubMed
    1. Jia Z. F., Zhang S. L., Cao X. Y., Zhou B. S., Jiang J. Interaction between Helicobacter pylori and host genetic variants in gastric carcinogenesis. Future Oncology. 2016;12(18):2127–2134. doi: 10.2217/fon-2016-0233. - DOI - PubMed
Feedback